Cited by 2Alzheimer's disease research and treatmentsCellular transport and secretionAutophagy in Disease and Therapy

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index; 7 of the 58 sources its claims cite were checked for support.

Hippocampal TMEM55B overexpression in the 5XFAD mouse model of Alzheimer's disease

Open access

Abstract

Dysfunction of the endosomal‐lysosomal network is a notable feature of Alzheimer's disease (AD) pathology. Dysfunctional endo‐lysosomal vacuoles accumulate in dystrophic neurites surrounding amyloid β (Aβ) plaques and may be involved in the pathogenesis and progression of Aβ aggregates. Trafficking and thus maturation of these dysfunctional vacuoles is disrupted in the vicinity of Aβ plaques. Transmembrane protein 55B (TMEM55B), also known as phosphatidylinositol‐4,5‐bisphosphate 4‐phosphatase 1 (PIP4P1) is an endo‐lysosomal membrane protein that is necessary for appropriate trafficking of endo‐lysosomes. The present study tested whether overexpression of TMEM55B in the hippocampus could prevent plaque‐associated axonal accumulation of dysfunctional endo‐lysosomes, reduce Aβ plaque load, and prevent hippocampal‐dependent learning and memory deficits in the 5XFAD mouse models of Aβ plaque pathology. Immunohistochemical analyses revealed a modest but significant reduction in the accumulation of endo‐lysosomes in dystrophic neurites surrounding Aβ plaques, but there was no change in hippocampal‐dependent memory or plaque load. Overall, these data indicate a potential role for TMEM55B in reducing endo‐lysosomal dysfunction during AD‐like Aβ pathology.

Overview

AI snapshot

Written from the paper’s full text.

TL;DR

Hippocampal overexpression of TMEM55B via AAV9 in 5XFAD mice modestly reduced LAMP1 accumulation in peri-plaque dystrophic neurites but did not alter Aβ plaque load or hippocampal-dependent memory. The authors conclude TMEM55B may have a limited role in reducing endo-lysosomal dysfunction during AD-like Aβ pathology.

Key findings

  • AAV9-TMEM55B-GFP treatment in 5XFAD mice significantly reduced LAMP1 intensity within peri-plaque regions (PPRs) compared with saline-treated 5XFAD mice (F(1, 8) = 8.363, p = 0.02), though the effect was modest.
  • PPR LAMP1 intensity was nearly two-fold greater than the whole hippocampal section average (F(1, 8) = 263.6, p < 0.0001), and PPR LAMP1-positive area normalized to hippocampal area did not differ between saline- and AAV-TMEM55B-GFP-treated mice (p = 0.9729).
  • No treatment effect was found on overall hippocampal LAMP1 intensity, overall hippocampal LAMP1 percent area, or Aβ (D54D2) plaque signal area (p = 0.7542).
  • Morris water maze probe trial performance did not differ by genotype or treatment for platform passes (genotype F(1, 16) = 0.05202, p = 0.8225; treatment F(1, 16) = 0.7511, p = 0.3989) or distance to platform (genotype F(1, 16) = 1.101, p = 0.3097; treatment F(1, 16) = 2.936, p = 0.1059); unexpectedly, 5XFAD mice spent more time in the target quadrant than WT mice (F(1, 16) = 8.725, p = 0.0093).

Methods

  • 5XFAD mice and WT littermates of both sexes received intrahippocampal stereotaxic injection of AAV9-TMEM55B-GFP or PBS at 2 months of age; behavioral testing occurred at 5 months, 90 days after injection.
  • Hippocampal-dependent spatial learning and memory were assessed with the Morris water maze; non-hippocampal memory was assessed with Novel Object Recognition, but NOR data were excluded because several mice failed to meet the minimum 20-second object interaction time.
  • Brains were processed for immunohistochemistry against LAMP1, Aβ (D54D2), and GFP, imaged with brightfield fluorescence or confocal microscopy, and analyzed with ImageJ, including a custom method to measure LAMP1 percent area and intensity exclusively within peri-plaque regions.

Limitations

  • The paper states that NOR data were excluded because several mice failed to meet the minimum object interaction time of 20 seconds, reducing some groups such that meaningful interpretation was not possible.
  • The authors state that 5XFAD is a pathologically aggressive Aβ model and suggest the intervention might be more effective in a model with slower Aβ pathological progression; they also note that 5XFAD and other FAD mice do not display robust age- or pathology-associated cognitive deficits on hippocampal and non-hippocampal memory tasks.
  • The authors state that additional studies using different Aβ pathology models, TMEM55B suppression, and more robust TMEM55B overexpression are necessary; they also note that TMEM55B-mediated feedback inhibition of TFEB may underlie the subtle effect observed. Evident from the text: the immunohistochemical and behavioral analyses used small group sizes (N = 4–6 mice), and the study reports only a modest reduction in PPR LAMP1 intensity without changes in plaque load or cognition.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1002/hipo.23586

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

7 of 58 cited sources checked · 2 supported · 1 flagged · accuracy not yet measured

  • Premisecitation

    5XFAD and other FAD mice do not display robust age- or pathology-associated cognitive deficits on hippocampal and non-hippocampal memory tasks.

    “Despite the aggressive rate of pathological Aβ aggregation and lysosomal disruption in the 5XFAD and other FAD mice, they do not display robust ageor pathology-associated cognitive deficits on hippocampal and non-hippocampal memory tasks (Jankowsky & Zheng, 2017;Oblak et al., 2021)”
    Quote in the paperSubstantial claim2 of 2 sources checked
    • cites Jankowsky & Zheng, 2017 source

      The Cognitive impairment subsection says that nearly all tested APP-overexpression models show spatial learning and memory deficits, and specifically reports cognitive decline in 5XFAD months after amyloid pathology. It cautions that the age and disease stage at which deficits are detected depend on the task, but does not support the categorical claim that these mice lack such deficits. (LLM, conf=0.88)

      Checked by a reasoning model — may be wrong.

      Experimental — accuracy not yet measured
    • cites Oblak et al., 2021 source

      The Results section reports no spatial working-memory deficit in 5XFAD mice at 6 or 12 months on a hippocampal spontaneous-alternation task. The Discussion likewise reports no consistent cognitive impairment in the tested mice, but says cognitive testing was limited in scope. The paper does not establish the claim for other FAD mice or for non-hippocampal memory tasks. (LLM, conf=0.88)

      Experimental — accuracy not yet measured
  • Premisecitation

    TMEM55B expression is dependent on TFEB.

    “Interestingly, while TMEM55B expression is dependent on TFEB (Willett et al., 2017), TMEM55B can actually inhibit TFEB nuclear translocation (Hashimoto et al., 2018) thus suppressing expression of lysosomal genes.”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites Willett et al., 2017 source

      The Results section, “TFEB and TFE3 upregulate TMEM55B in response to starvation,” reports that TFEB increases TMEM55B mRNA and protein and that the starvation-induced increase is TFEB/TFE3-dependent. The claim omits both the starvation condition and TFE3’s role, making TFEB dependence sound more general than the evidence establishes. (LLM, conf=0.85)

      Experimental — accuracy not yet measured
  • Premisecitation

    TMEM55B gene expression does not change throughout the lifespan of 5XFAD mice.

    “Notably, TMEM55B gene expression does not change throughout the lifespan of 5XFAD mice, but LAMP1, TFEB, and TFE3 gene expression increases after 12 months of age (Forner et al., 2021).”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites Forner et al., 2021 source

      The Technical Validation section, “Gene expression changes in 5xFAD mice” (Fig. 8; page unavailable), reports age-related changes in differentially expressed genes but does not identify TMEM55B or establish that its expression remains unchanged. Searches for TMEM55B and for LAMP1, TFEB, and TFE3 expression after 12 months found no passage in our copy establishing the cited sentence’s gene-specific claims. (LLM, conf=0.72)

      Experimental — accuracy not yet measured
  • Premisecitation

    Dysfunction of the endosomal-lysosomal system is directly linked with Aβ deposition.

    “Dysfunction of the endosomallysosomal system is also directly linked with Aβ deposition (Lee et al., 2022), oxidative stress (Wendt et al., 2022), and synaptic dysfunction (Adalbert et al., 2009).”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites Lee et al., 2022 source
  • Findingown data

    Overall hippocampal LAMP1 signal intensity did not differ among genotype or treatment groups.

    “Although LAMP1 signal intensity was equal among all experimental groups (F (1, 14) = 0.7831, p = 0.3911, main effect of genotype; F (1,14) = 0.3892, p = 0.5428, main effect of treatment; Figure 3B),”
    Quote in the paperNot a substantial claim
  • It may state two separate claims as one. 11
  • Probably not a substantial claim. 17
  • It may state two separate claims as one.

    Premisecitation

    LAMP1 is mislocalized to dystrophic neurites in 5XFAD models and in human Alzheimer's disease.

    “membrane protein 1 (LAMP1) is mislocalized to dystrophic neurites in 5XFAD models (Forner et al., 2021;Gowrishankar et al., 2015;Wickline et al., 2023) and human AD (Barrachina et al., 2006).”
    Quote in the paperSubstantial claim1 of 3 sources checked
    • cites Forner et al., 2021 source
    • cites Wickline et al., 2023 source
    • cites Barrachina et al., 2006 source
  • It may state two separate claims as one.

    Premisecitation

    AAV9 has robust tropism for neurons and displays high expression levels in the hippocampus.

    “While the promoter was cytomegalovirus (CMV), AAV9 has robust tropism for neurons and displays high expression levels in the hippocampus (Aschauer et al., 2013).”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites Aschauer et al., 2013 source

      The Results (Efficiency of transgene expression; page unavailable) rank AAV9 highest for expression in the mouse hippocampus. The Discussion (page unavailable) describes strong expression in cortical neurons, but does not establish equally robust neuronal tropism across brain regions; the claim omits that distinction. (LLM, conf=0.83)

      Experimental — accuracy not yet measured
  • It may state two separate claims as one.

    Findingown data

    Single intrahippocampal AAV-TMEM55B-GFP injection efficiently labels hippocampus and TMEM55B-GFP colocalizes with endo/lysosomal marker LAMP1.

    “Figure 2 . Figure 2. Single intrahippocampal AAV-TMEM55B-GFP injection efficiently labels hippocampus and TMEM55B-GFP colocalizes with endo/lysosomal marker LAMP1.”
    Quote in the paperSubstantial claim
  • It may state two separate claims as one.

    Findingown data

    Focal GFP expression was found near plaques and in neurons and overlapped with LAMP1 endo-lysosomal staining.

    “Focal GFP expression was also found near plaques and in neurons and overlapped with LAMP1 endo-lysosomal staining (Figure 2B & C).”
    Quote in the paperNot a substantial claim
  • It may state two separate claims as one.

    Findingown data

    In mice injected with AAV-TMEM55B-GFP there was widespread GFP expression in the hippocampus that extended to other brain areas, which was not present in control mice.

    “In mice injected with AAV-TMEM55B-GFP, there was widespread GFP expression in the hippocampus that extended to other brain areas that was not present in control mice (Figure 2A).”
    Quote in the paperSubstantial claim
  • Probably not a substantial claim.

    Premisecitation

    Numerous genetic perturbation and pharmacological studies support a protective role of TFEB activation in a variety of neurodegenerative disease models.

    “Further, numerous genetic perturbation and pharmacological studies support the protective role of TFEB activation in a variety of neurodegenerative disease models (Gu et al., 2022;Song et al., 2021).”
    Quote in the paperSubstantial claim0 of 2 sources checked
    • cites Gu et al., 2022

      Couldn’t be matched to a paper in Crossref, so it can’t be checked.

    • cites Song et al., 2021

      Couldn’t be matched to a paper in Crossref, so it can’t be checked.

  • It may state two separate claims as one.

    Premisecitation

    TMEM55B transcription is regulated by the lysosomal regulator TFEB, which is dysregulated in Alzheimer's disease.

    “TMEM55B transcription is regulated by the master autophagic and lysosomal regulator TFEB (Willett et al., 2017) which is dysregulated in AD (Zhang & Zhao, 2015).”
    Quote in the paperSubstantial claim0 of 2 sources checked
    • cites Willett et al., 2017 source
    • cites Zhang & Zhao, 2015 source
  • Probably not a substantial claim. The paper’s conclusions may not depend on it.

    Premisecitation

    Accumulation of lysosomes around amyloid β plaques is associated with increased oxidative stress.

    “Additionally, accumulation of lysosomes around Aβ plaques is associated with increased oxidative stress (Wendt et al., 2022).”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites Wendt et al., 2022 source
  • It may state two separate claims as one.

    Premisecitation

    Disruption of lysosomal trafficking and maturation in Alzheimer's disease pathology leads not only to cellular stress but also to accumulation of extracellular amyloid β.

    “When this lysosomal trafficking and maturation process is disrupted in AD pathology (Lie et al., 2022), it not only leads to cellular stress but also the accumulation of extracellular amyloid β (Aβ) (Lee et al., 2022).”
    Quote in the paperSubstantial claim0 of 2 sources checked
    • cites Lie et al., 2022 source
    • cites Lee et al., 2022 source
  • Probably not a substantial claim. The paper’s conclusions may not depend on it.

    Premisecitation

    TMEM55B regulation of lysosome positioning and trafficking is independent from its phosphatase function.

    “TMEM55B regulates lysosome positioning and trafficking via interaction with the JIP4 motor protein adapter (Willett et al., 2017) independently from its phosphatase function (Takemasu et al., 2019) but dependent on S-palmitoylation (Rudnik et al., 2022).”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites Takemasu et al., 2019 source
  • Probably not a substantial claim.

    Premisecitation

    The downstream mechanism of TFEB's protective actions in Alzheimer's disease models most likely involves a restoration of lysosomal homeostasis.

    “The downstream mechanism of TFEB's protective actions in AD models are still poorly understood, but most likely involves a restoration of lysosomal homeostasis (Gu et al., 2022;Song et al., 2021).”
    Quote in the paperSubstantial claim0 of 2 sources checked
    • cites Gu et al., 2022

      Couldn’t be matched to a paper in Crossref, so it can’t be checked.

    • cites Song et al., 2021

      Couldn’t be matched to a paper in Crossref, so it can’t be checked.

  • It may state two separate claims as one.

    Interpretationcitation

    TMEM55B activity may mitigate amyloid β plaque-associated lysosomal dysregulation, perhaps by promoting retrograde trafficking.

    “This suggest that TMEM55B activity may mitigate Aβ plaque-associated lysosomal dysregulation perhaps by promoting retrograde trafficking (Willett et al., 2017).”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites Willett et al., 2017 source
    • Rests on an assumption: LAMP1 immunopositivity within peri-plaque regions quantitatively reflects the accumulation of dysfunctional endo-lysosomes in dystrophic neurites.
    • Rests on an assumption: AAV9-mediated hippocampal expression of TMEM55B-GFP yields functionally active TMEM55B in vivo.
  • Probably not a substantial claim. The paper’s conclusions may not depend on it.

    Premisecitation

    TMEM55B localizes to late endosomes and lysosomes.

    “TMEM55B localizes to late endosomes and lysosomes and its overexpression mediates lysosomal degradation of internalized epidermal growth factor receptors (Ungewickell et al., 2005).”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites Ungewickell et al., 2005 source
  • Probably not a substantial claim. The paper’s conclusions may not depend on it.

    Premisecitation

    TMEM55B regulation of lysosome positioning and trafficking is dependent on S-palmitoylation.

    “TMEM55B regulates lysosome positioning and trafficking via interaction with the JIP4 motor protein adapter (Willett et al., 2017) independently from its phosphatase function (Takemasu et al., 2019) but dependent on S-palmitoylation (Rudnik et al., 2022).”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites Rudnik et al., 2022

      Couldn’t be matched to a paper in Crossref, so it can’t be checked.

  • Probably not a substantial claim. The paper’s conclusions may not depend on it.

    Study design and conductown data

    Novel Object Recognition data were excluded because several mice failed to meet the minimum object interaction time of 20 seconds, reducing some experimental groups such that a meaningful interpretation of the results was not possible.

    “However, NOR data was excluded from this publication because several mice failed to meet the minimum object interaction time of 20 seconds which resulted in some experimental groups being reduced such that a meaningful interpretation of the results was not possible.”
    Quote in the paperNot a substantial claim
  • It may state two separate claims as one.

    Study design and conductcitation

    PBS serves as an adequate control for these experiments, because the endo-lysosomal pathway targeted here is not greatly affected by AAV-GFP.

    “Our previous work demonstrates that about 400 transcripts, many related to ribosomal processing, are upregulated in AAV-GFP treated hippocampal neurons compared to PBS treated hippocampal neurons (Hopp et al., 2018), suggesting that the endo-lysosomal pathway targeted herein is not greatly affected by AAV-GFP and that PBS can serve as an adequate control for the experiments herein.”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites Hopp et al., 2018 source
  • Probably not a substantial claim. The authors may not put it forward as true.

    Premisecitation

    Activating TFEB ameliorates Aβ pathology.

    “Others have found that activating TFEB, the master transcriptional regulator of lysosomal biogenesis, ameliorates Aβ pathology (Xiao et al., 2015).”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites Xiao et al., 2015 source
  • Probably not a substantial claim. The paper’s conclusions may not depend on it.

    Premisecitation

    Appropriate lysosomal trafficking is vital for maturation and acidification.

    “Appropriate lysosomal trafficking is vital for maturation and acidification (Nixon, 2017).”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites Nixon, 2017 source
  • Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.

    Premisecitation

    TMEM55B regulates surface expression of low-density lipoprotein receptor but not transferrin receptor or lipoprotein receptor 1.

    “TMEM55B also regulates surface expression of low-density lipoprotein receptor but not transferrin receptor or lipoprotein receptor 1 (Medina et al., 2014;Qin et al., 2020) suggesting its role in receptor trafficking may be cargo specific.”
    Quote in the paperNot a substantial claim0 of 2 sources checked
    • cites Medina et al., 2014 source
    • cites Qin et al., 2020 source
  • Probably not a substantial claim.

    Premisecitation

    Defects in the endosomal-lysosomal network can impact homeostatic cellular processes including cell signaling, molecular trafficking, and clearance pathways.

    “Defects in the endosomal-lysosomal network can impact numerous homeostatic cellular processes including cell signaling, molecular trafficking, and clearance pathways (Nixon, 2017).”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites Nixon, 2017 source
  • Probably not a substantial claim. The paper’s conclusions may not depend on it.

    Premisecitation

    TMEM55B overexpression mediates lysosomal degradation of internalized epidermal growth factor receptors.

    “TMEM55B localizes to late endosomes and lysosomes and its overexpression mediates lysosomal degradation of internalized epidermal growth factor receptors (Ungewickell et al., 2005).”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites Ungewickell et al., 2005 source
  • It may state two separate claims as one.

    Premisecitation

    TMEM55B can inhibit TFEB nuclear translocation, thus suppressing expression of lysosomal genes.

    “Interestingly, while TMEM55B expression is dependent on TFEB (Willett et al., 2017), TMEM55B can actually inhibit TFEB nuclear translocation (Hashimoto et al., 2018) thus suppressing expression of lysosomal genes.”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites Hashimoto et al., 2018 source
  • Probably not a substantial claim. The paper’s conclusions may not depend on it.

    Premisecitation

    Dysfunction of the endosomal-lysosomal system is directly linked with oxidative stress.

    “Dysfunction of the endosomallysosomal system is also directly linked with Aβ deposition (Lee et al., 2022), oxidative stress (Wendt et al., 2022), and synaptic dysfunction (Adalbert et al., 2009).”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites Wendt et al., 2022 source
  • Probably not a substantial claim.

    Premisecitation

    Activating TFEB ameliorates amyloid β pathology.

    “Others have found that activating TFEB ameliorates Aβ pathology (Xiao et al., 2015).”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites Xiao et al., 2015 source
  • Probably not a substantial claim. The paper’s conclusions may not depend on it.

    Interpretationcitation

    TMEM55B's role in receptor trafficking may be cargo specific.

    “suggesting its role in receptor trafficking may be cargo specific.”
    Quote in the paperNot a substantial claim
  • Probably not a substantial claim.

    Premisecitation

    Presenilin function is disrupted in patients with familial AD mutations in PS.

    “Presenilin (PS) function, which is disrupted in patients with familial AD mutations in PS, is associated with dysfunctional lysosomal proteolysis and autophagy (Lee et al., 2010;Lie et al., 2022;Neely et al., 2011;Reddy et al., 2016)”
    Quote in the paperSubstantial claim0 of 3 sources checked
    • cites Lee et al., 2010 source
    • cites Lie et al., 2022 source
    • cites Neely et al., 2011 source
  • Probably not a substantial claim. The paper’s conclusions may not depend on it.

    Premisecitation

    TMEM55B is implicated in direct regulation of endo-lysosomal acidification, potentially independently of its trafficking functions.

    “TMEM55B is also implicated in direct regulation of endo-lysosomal acidification, potentially independently of its trafficking functions (Hashimoto et al., 2018;Takemasu et al., 2019).”
    Quote in the paperNot a substantial claim0 of 2 sources checked
    • cites Hashimoto et al., 2018 source
    • cites Takemasu et al., 2019 source
27 of 27
  • The paper relies on this without support.

    LAMP1 immunopositivity within peri-plaque regions quantitatively reflects the accumulation of dysfunctional endo-lysosomes in dystrophic neurites.

    “Taken together, a change in area coverage without a change in intensity and the anatomical distribution within the representative images (Figure 3A and 2C middle panel) illustrate that 5XFAD Aβ pathology induces LAMP1 signal translocate away from cell bodies to instead accumulate in axonal swellings in peri-plaque regions (PPRs).”
    “Immunohistochemical analyses revealed a modest but significant reduction in the accumulation of endo-lysosomes in dystrophic neurites surrounding Aβ plaques, but there was no change in hippocampal-dependent memory or plaque load.”
  • The paper relies on this without support.

    AAV9-mediated hippocampal expression of TMEM55B-GFP yields functionally active TMEM55B in vivo.

    “GFP was fused to the N-terminal of human TMEM55B domain in the plasmid (a kind gift from Jose Martina and Rosa Puertollano) as previously described (Willett et al., 2017).”
  • The paper relies on this without support.

    Few studies have examined the function of TMEM55B.

    “Few studies have examined the function of TMEM55B.”
  • The paper relies on this without support.

    The 5XFAD mice used here express mutant PS1 with familial AD mutations.

    “the 5XFAD mice used here express mutant PS1 with familial AD mutations.”
  • The paper relies on this without support.

    The 5XFAD mouse model is an aggressive model of Aβ pathology with rapid Aβ-plaque pathology relative to the mouse lifespan.

    “The 5XFAD mouse model which overexpression APP and presenilin with a combined 5 familial Alzheimer's disease mutations, is considered a pathologically”
5 of 5

Statistics recomputed

Every reported test result, recomputed from its test statistic and degrees of freedom. A result shows as not adding up only once an independent check has confirmed it.

  • ConsistentF(4, 64) = 50.8reported p < .0001 · recomputed p < .001

    “F (4, 64) = 50.8,p < .0001”

  • ConsistentF(1, 16) = 0.052reported p = .8225 · recomputed p = .822

    “F (1, 16) = 0.05202, p = .8225”

  • ConsistentF(1, 16) = 0.7511reported p = .3989 · recomputed p = .399

    “F (1, 16) = 0.7511, p = .3989”

  • ConsistentF(1, 16) = 1.101reported p = .3097 · recomputed p = .310

    “F (1, 16) = 1.101, p = .3097”

  • ConsistentF(1, 16) = 2.936reported p = .1059 · recomputed p = .106

    “F (1, 16) = 2.936, p = .1059”

  • ConsistentF(1, 16) = 8.725reported p = .0093 · recomputed p = .009

    “F (1, 16) = 8.725, p = .0093”

  • ConsistentF(1, 14) = 0.7831reported p = .3911 · recomputed p = .391

    “F (1, 14) = 0.7831, p = .3911”

  • ConsistentF(1, 14) = 0.3892reported p = .5428 · recomputed p = .543

    “F (1,14) = 0.3892, p = .5428”

  • ConsistentF(1, 14) = 0.0003reported p = .9865 · recomputed p = .986

    “F (1, 14) = 0.0002968, p = .9865”

  • ConsistentF(1, 8) = 263.6reported p < .0001 · recomputed p < .001

    “F (1, 8) = 263.6,p < .0001”

  • ConsistentF(1, 8) = 8.363reported p = .02 · recomputed p = .020

    “F (1, 8) = 8.363, p = .02”

11 of 11

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

  • Figure 1C caption contradicts the reported genotype effect

    Major

    The results report a significant genotype effect on time spent in the target quadrant, but the Figure 1C caption says there was no genotype effect on that measure.

1 of 1

Citations

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Metadata

Authors
Odfalk, K. F., Wickline, J. L., Smith, S., Dobrowolski, R., & Hopp, S. C.
Affiliations
  • The University of Texas at San Antonio Health Science Center (US)
  • Rutgers, The State University of New Jersey (US)
Corresponding author
Hopp, Sarah C.
Venue
Hippocampus
Publisher
Wiley
Published
2023-11-14
Volume
34
Issue
1
Pages
29-35
ISSN
  • 1050-9631 (ISSN-L)
  • 1098-1063
OpenAlex
W4388659730
Cited by
2
References
30
Citations by year
2026: 2
FWCI
0.20
Type
journal article
Language
en
Open access
Locations
  • Hippocampus (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Institutes of Health (NS082145, AG066747)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular transport and secretion
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
Keywords
Alzheimer's disease, 5xFAD mice, amyloid plaques, dystrophic neurites, learning and memory impairment, lysosomal trafficking
MeSH terms
Phosphoinositide Phosphatases, Alzheimer Disease, Animals, Disease Models, Animal, Memory Disorders, Mice, Transgenic, Amyloid beta-Peptides, Mice, Plaque, Amyloid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review